Top Stories
Earlier this year, CEO Luke Miels singled out felcorekibart as one of the pipeline programmes that could help GSK raise its game.
The deal pairs a Nasdaq listing with Ambros' late-stage pain drug neridronate and an oversubscribed $150M private placement.
The investment is expected to double the facility's size while creating 250 high-wage roles linked to the manufacture drug delivery devices.
Bristol Myers Squibb is the latest pharma giant to tap Chai's AI models, following recent deals with Pfizer, Novartis, Eli Lilly and argenx.
Amplitude Therapeutics will use its trans-amplifying RNA (taRNA) technology to discover infectious disease vaccine candidates.
Conference News
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentationAdditionally, new data...
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today...
According to Fidelity, RBC Capital Markets said Merck & Co.’s momentum remains strong, driven by better-than-expected cancer vaccine data, but its valuation limits further upside.RBC highlighted upcom...
On August 19, 2026, Mountain Time (MT)，the official website of the 2026 World Conference on Lung Cancer (WCLC) released the abstracts selected for this year’s congress. Seven lung cancer studies of He...
